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INTRODUCTION
Food allergy, which results from an exaggerated and inappro-
priate immune response to certain foods, has become a major 
public health problem in westernized countries, and also a ma-
jor source of anxiety and stress for both affected children and 
their parents. In the US, the overall prevalence of food allergy 
has been estimated to be 3.5%
1 and has recently witnessed at 
least an 18% increase from 1997 to 2007, particularly in young 
children.
2 The most common allergenic foods in children and 
their estimated prevalence in North America are: milk (2.5%), 
egg (1.5%), peanuts (1%), tree nuts (0.5%), shellfish (0.1%), fish 
(0.1%), and wheat/soy (0.4%).
3-6 Definitive and accurate assess-
ment of the prevalence of food allergy however, is limited by the 
different definitions of food allergy and the variability of diag-
nostic methods utilized in various studies.
7
While food allergy can be divided broadly into IgE-mediated 
and non-IgE-mediated disease, in this review, we will focus on 
IgE-mediated food allergy, which can manifest as urticaria, an-
gioedema, wheezing and respiratory distress, vomiting, diar-
rhea, cardiovascular collapse and anaphylaxis generally occur-
ring with 1-60 minutes after exposure. Non-IgE-mediated food 
allergy manifests as celiac disease, food protein-induced enter-
opathy, eosinophilic gastroenteritis or lactose intolerance. With 
IgE-mediated diseases however, the clinical presentation, degree 
of severity, and natural course of food allergy as well as the fre-
quency of reactions vary widely among different individuals 
and even within the same individual. Nevertheless, across all 
ages, food allergy represents the most common cause of ana-
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phylaxis seen in the emergency department and is associated 
with increasing hospitalizations and rarely death.
8-11 Allergy to 
peanuts and tree nuts has been shown to be associated with 
more severe anaphylactic reactions,
8,9 and a lower chance of 
spontaneous resolution when compared to milk and egg aller-
gies.
Currently, there is no effective, definitive and curative therapy 
for food allergy. The standard therapeutic approach consists of 
allergen avoidance, nutritional counseling and rapid medical 
treatment in case of accidental exposure. In this review, we will 
discuss several therapeutic approaches for food allergy that are 
currently being investigated. In particular, we will discuss oral 
immunotherapy (OIT) and a novel approach utilizing a combi-
nation of Xolair (omalizumab) and OIT.
Different forms of IgE-mediated food allergy
One can subdivide IgE-mediated food allergy into three sub-
types: transient, persistent, and oral allergy syndrome (also 
known as pollen associated food allergy syndrome).
12 Each form 
differs from the others in terms of prognosis, and each has a dif-
ferent therapeutic approach.
Review
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Oral allergy syndrome is manifested mainly by oral symptoms 
(lips, mouth, and throat) that occur after ingestion of certain 
fresh foods of plant origin in patients with allergic rhinitis/pol-
len allergy. It is thought to be due to immunologic cross-reac-
tivity between plant pollen allergens and proteins found in cer-
tain related fruits and vegetables.
13 Patients with transient food 
allergy usually outgrow their allergy over time, and therefore 
food avoidance is generally the recommended treatment, al-
though it is possible that immunotherapy may hasten food al-
lergy resolution. Allergy to cow’s milk, egg, wheat and soy in 
children are generally transient, with 80% resolving by age 16 
years. In contrast, persistent food allergy usually starts in child-
hood and persists into adulthood. Allergy to peanut, tree nuts, 
fish, and shellfish are usually persistent, and only about 20% of 
patients outgrow peanut/tree nut allergy. Distinguishing tran-
sient from persistent forms of food allergy is critical early on for 
instituting appropriate therapeutic strategies, particularly since 
patients with persistent food allergy may be candidates for de-
sensitization therapies. However, some patients with persistent 
food allergy manifest a less favorable therapeutic response in-
cluding failure of desensitization and/or achievement of oral 
tolerance (see below). Note that the distinction between tran-
sient and persistent food allergy is not always clear. While foods 
like milk and egg tend to be associated with transient food al-
lergy, over the past decade these food allergies have persisted 
in individuals for greater time periods, for reasons that are not 
fully understood. In addition, several studies have suggested 
that higher levels of baseline food specific IgE may be useful for 
identifying persistent food allergy in patients with milk or egg 
allergy.
14 This concept might also be applicable to peanut or tree 
nut allergy.
THERAPEUTIC STRATEGIES/APPROACHES FOR FOOD 
ALLERGY
Allergen avoidance
The classical approach to food allergy is complete avoidance 
of the offending allergen. In many patients with transient food 
allergy, there is a hope that the food allergy can be outgrown 
over time. However, this allergen avoidance approach is extreme-
ly challenging for patients and their families and requires con-
stant vigilance and active precautions. Adherence is particular-
ly difficult with foods that are common, ubiquitous ingredients, 
resulting in a high risk of accidental exposure, or with foods that 
are not clearly included in labels.
15,16 Because of the required 
vigilance and possible risk of reactions this treatment modality 
has a negative impact on the emotional, psychological and so-
cial wellbeing of children and their families.
17
Immunotherapy
Immunotherapy for oral allergy syndrome
The cross reactivity between major allergenic epitopes of pol-
lens and those of certain foods has suggested a role for specific 
immunotherapy with certain pollens (e.g., birch) in patients 
with oral allergy syndrome. Subjects treated with subcutaneous 
pollen immunotherapy or sublingual immunotherapy (SLIT) 
have experienced variable beneficial effects on their oral symp-
toms and skin test reactivity to certain plant foods.
13,18-21 These 
effects were predominantly reported in adults mono-sensitized 
to birch tree pollen and treated with high dose pollen immuno-
therapy. In 49 adults with birch-induced allergic rhinitis and 
oral allergy syndrome to apple, a significant reduction (50% to 
95%) or complete resolution of apple-induced oral symptoms 
was demonstrated in 84% of treated subjects compared with no 
benefit in control subjects (P<0.001). Additionally, a reduction 
in skin test reactivity to fresh apple was seen in 88% of these 
subjects after 12 months of birch immunotherapy.
13 Although 
18 months post cessation of birch immunotherapy the majority 
of subjects reverted to positive skin prick test (SPT) responses, 
more than 50% could tolerate ingestion of apple. In another 
study, on the other hand, SLIT with birch pollen extract did not 
significantly reduce apple-induced oral allergy syndrome symp-
toms in adults with birch-induced allergic rhinitis.
22 Therefore, 
treatment recommendations for oral allergy syndrome remains 
controversial.
Immunotherapy for transient food allergy with extensively 
heated food
Treatment of egg and milk proteins with high temperatures 
denatures allergenic proteins rendering them less allergenic. 
This observation has led to OIT using heated food proteins.
23,24 
Several studies have shown that most allergic subjects treated 
with heated (baked) egg/milk tolerated the heated food protein 
(70% of children with egg allergy and 75% of children with milk 
allergy). Although some food proteins show enhanced allerge-
nicity with heating, as is the case with peanuts,
25 treatment of 
egg or milk allergic patients with baked forms of these foods is 
an appealing alternative to strict food avoidance. This approach 
may hasten the resolution of transient food allergy, but may not 
be effective for patients with severe food allergy, or those with 
high milk-specific IgE.
Sublingual immunotherapy
For patients with persistent food allergy, several different forms 
of immunotherapy are currently being explored. SLIT with food 
allergens is one of these approaches, first reported in 2003.
26 In 
this approach, the food is administered sublingually, held in 
the mouth for few minutes, and then spit or swallowed. Several 
studies, with hazelnut, milk, peanut, and peach have demon-
strated the benefit of SLIT in increasing the amount of the food 
tolerated on double-blind placebo-controlled food challenge 
(DBPCFC).
27-30 Side effects are generally mild, primarily limited 
to oropharyngeal symptoms, and rarely requiring oral antihis-
tamine administration. However, the maximum dose that can Oral Immunotherapy for Food Allergy
Allergy Asthma Immunol Res. 2013 January;5(1):3-15.  http://dx.doi.org/10.4168/aair.2013.5.1.3
AAIR 
5 http://e-aair.org
be administered sublingually is limited, which may limit the 
maximum dose of food that can be ultimately tolerated. Recent 
studies suggest that combining SLIT with subsequent OIT (see 
below) may benefit from the safety profile of SLIT and potential 
for achieving higher doses of food with OIT. Further studies are 
needed to standardize the method and demonstrate its safety 
in larger numbers of patients.
Epicutaneous immunotherapy
Another approach for persistent food allergy is epicutaneous 
immunotherapy (EIT), in which patients receive three 48-hour 
skin patch applications (1 mg of skimmed milk powder) per 
week for 3 months. Such an approach was studied in small ran-
domized placebo controlled pilot study with 18 children with 
cow’s milk allergy (mean age, 3.8 years; age range, 10 months to 
7.7 years).
31 Subjects in the active treatment group consistently 
showed higher doses of tolerated milk on food challenges dur-
ing follow up visits when compared to subjects in the placebo 
group (increase of threshold doses at follow-up oral milk chal-
lenge. In both groups at 3 months, cow’s milk-specific IgE levels 
did not change significantly from baseline. Adverse effects con-
sisted mostly of local cutaneous reactions and discomfort (pru-
ritis and eczema) and repeated doses of diarrhea in one child 
but did not include any severe systemic reactions. While EIT 
appears safe, clearly, additional studies are required to examine 
efficacy in terms of additional foods, and what are the maxi-
mum doses that can be applied epicutaneously and tolerated 
orally.
Subcutaneous immunotherapy
The use of subcutaneous immunotherapy (SCIT) in persistent 
food allergy was abruptly discontinued after reports of fatal re-
actions with peanut injections. A double-blind placebo-con-
trolled trial
32 with 12 patients assigned in a 1 to 1 ratio to either 
peanut extract or control showed that SCIT with peanut was ef-
fective, although a high rate of severe systemic reactions was 
noted in the treatment group. Consequently, this approach is 
no longer used.
Oral immunotherapy
OIT is currently the most actively and extensively investigated 
approach for persistent food allergy. This method, in which the 
food is usually given orally starting a low doses and increasing 
at variable rates, is based on the assumption that oral/intestinal 
exposure to antigens normally leads to tolerance, and on many 
years of experience with protocols for oral antibiotic desensiti-
zation. Oral food immunotherapy protocols usually include an 
initial rapid dose escalation phase, followed by a slower build 
up phase to reach the desired maintenance dose. Over the past 
eight years, many studies (discussed below, and in Table) have 
shown that OIT is effective and reasonably safe, although aller-
gic reactions occur in the majority of treated patients.
- Cow’s milk OIT
Several studies have demonstrated that OIT with milk is effec-
tive in desensitizing patients with cow’s milk allergy. In 2004, 
Meglio et al.
33 reported on a 6 month protocol of OIT in milk al-
lergic patients with the goal of enabling subjects to tolerate a 
daily dose of 200 mL (6,700 mg) of cow’s milk (CM). 21 patients, 
aged 5 to 10 years, diagnosed with milk allergy either by means 
of DBPCFC or by a strong positive history of reaction to CM, were 
enrolled. The doses ranged from 0.06 mg of CM protein to a 
maximum of 200 mL. Three of the 21 enrolled patients failed 
because of allergic reactions after minimal amounts of diluted 
milk. 15 of the subjects (71.4%) were fully desensitized (daily in-
take of 200 mL of CM), and 3 (14.3%) were partially desensi-
tized (daily intake of 40-80 mg of CM).
In a placebo controlled clinical trial by Skripak et al.,
34 20 pa-
tients, aged 6 to 17 years, with IgE-mediated milk allergy, were 
randomly assigned in a 2 to 1 ratio to milk powder or placebo 
powder. The mean milk specific IgE level at enrollment was 
34.8 kUA/L (range 4.86-314 kUA/L) and 14.6 kUA/L (range 0.93-
133.4 kUA/L) for active and placebo groups respectively. All pa-
tients underwent baseline DBPCFC. The study was divided into 
3 phases: 1) Rapid dose escalation with an initial dose of 0.4 mg 
of milk protein and subsequent doubling doses administered 
every 30 minutes up to a maximum of 50 mg (cumulative dose 
of 98.7 mg) and a minimum of 12 mg (cumulative dose of 23.7 
mg). 2) Home dosing with an initial dose corresponding to the 
maximum dose tolerated on the escalation day and followed by 
a dose increase from 75 mg to 500 mg every 1 to 2 weeks. 3) 
Maintenance phase: daily consumption of 500 mg (15 mL of 
milk) for a period of 13 weeks. A second DBPCFC, preformed at 
the end of the maintenance phase, showed an increase in the 
threshold of sensitivity to milk in the active treatment group 
from a baseline median of 40 mg to post desensitization medi-
an of 5,100 mg (range 2,540 to 8,140 mg) whereas no change 
was observed in the control group.
In a larger placebo controlled trial, Longo et al.
35 enrolled 60 
patients with severe milk allergy, all with milk specific IgE levels 
above 85 kUA/L. Patient, aged 5 to 17 years, were randomly as-
signed, in a 1 to 1 ratio, to receive either gradually increasing 
amounts of cow’s milk (1 part of cow’s milk and 9 parts of an 
amino acid-based infant formula modified with vanilla flavor) 
or placebo. Subjects underwent a baseline DBPCFC and were 
eligible to enter the study if they reacted at doses of 0.8 mL or 
less of cow’s milk. The protocol consisted of an in hospital 10-
day rush phase during which increasing doses of diluted milk 
were given each day. The home phase consisted of a 1 mL in-
crease every second day and the percentage dose increase was 
adjusted to meet every person’s level of confidence and was 
guided by the severity and frequency of adverse events. After 
one year, 36% were successfully desensitized (daily intake of 
150 mL or more of cow’s milk), 54% were partially desensitized 
(daily intake of 5 mL to 150 mL) and 10% withdrew because of Khoriaty et al.
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Table. Safety of oral immunotherapy
Study Averse events Nature Interventions Withdrawal rate
Meglio
(Milk)
- Transient
- Rate: 13/21 
- Moderate asthma, angioedema, 
itchy throat, abdominal pain, 
utricaria
- Only Cetirizine No withdrawal
Skirpak
(Milk)
- All subjects had at least one ad-
verse reaction
- Median percentage of doses 
with reaction per child:
1) Treatment group: 35%
2) Placebo group: 1%
- Mostly local symptoms then gas-
trointestinal then lower respira-
tory
- 90% were transient and required 
no treatment 
- Epinephrine: only to active 
group, was given 4 times (0.2% 
of total doses): 2 doses during 
build up phase and 2 doses dur-
ing maintenance phase.
- Diphenydramine: 10.2% of to-
tal doses in active group versus 
1.1% of total doses in placebo 
group
No withdrawal
Longo
(Milk)
- Treatment group:
- All subjects in treatment group 
had at least one adverse reac-
tion 
- Control group: 6/30 (20%) had 
mild reactions because of acci-
dental exposure to milk
- Mainly cutaneous (urticaria), an-
gioedema, abdominal symptoms
- No intravenous epinephrine use
- Intramuscular epinephrine: 4 
times in 4 children during rush 
phase versus once in one pa-
tient during home dosing
- Nebulized epinephrine: 22 
times in 18 patients during rush 
phase verus 9 times in 6 chil-
dren during home dosing 
- Oral steroids: 16 times in 8 chil-
dren during rush phase verus 35 
times in 17 children during home 
dosing
- 10% (3 patients)
- Reasons: Side effects (abdomi-
nal/respiratory)
Umetsu
(Milk)
- All patients experienced some 
adverse events 
- Most required no treatment
- Mean frequency for total reac-
tions: 1.6%
- No allergic reactions to omali-
zumab
- Most common
Reactions: local (mostly pruritus 
or urticaria) and/or gastrointesti-
nal (e.g., abdominal pain), occur-
ring with a frequency of 1%.
- Mild (1%) 
- Moderate (0.3%)
- Severe reactions (0.1%)
- Epinephrine: 3 patients (1 by 
physician and 2 by parents at 
home)
- Antihistamines: other reactions
Drop out rate: 1/11 
Reason: abdominal migraines
Eosinophilic eosophagitis was 
ruled out
Wood
(Milk)
- Most reactions were mild
- 29% of SLIT doses
- 23% of OIT doses
- Same overall reaction rates in all 
groups
- More multisystem reactions in 
OIT compared to SLIT (11 times 
more)
- No diffrences between OITA and 
OITB groups.
- Oral
- Gastrointestinal
- Skin-Upper respiratory
- Lower respiratory
- Multisystem
- Epinephrine: 
· twice in SLIT group 
· 4 times in OIT group: twice at 
home during updosing, once 
during maintenance, and once 
during office updosing.
- Antihistamines: used more in 
the OIT groups
Drop out rate: 2/30
Reasons:
- 1 in OITB group during dose es-
calation because of persistent 
eczema exacerbation
- 1 in OITA group during mainte-
nance because of concerns of 
therapy- induced eosinphilic 
esophagitis.
(Continued to the next page)
allergic side effects. None of the subjects in the control group 
was able to tolerate 5 mL of cow’s milk. These results suggested 
that OIT could work in many but not all patients with severe 
milk allergy.
A recent open-label randomized study done by Keet et al.,
36 
compared the efficacy and safety of SLIT and OIT. 30 patients 
with IgE-mediated cow’s milk allergy, aged 6 to 17 years, were 
randomly assigned to SLIT alone or to SLIT followed by OIT. 
Initially, all study subjects received SLIT alone for a minimum 
of 4 weeks up to a dose of 3.7 mg. Dose escalation was subse-
quently continued with randomization into 3 groups: 1) SLIT 
with a goal dose of 7 mg and a minimum of 7 updosing visits; 2) 
OIT A with a goal of 2 g orally and a minimum of 19 updosing 
visits; 3) OIT B with a goal of 1 g orally with a minimum of 19 Oral Immunotherapy for Food Allergy
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updosing visits. A second DBPCFC was performed 12 weeks af-
ter achieving the target dose and was followed by a 48 weeks of 
daily maintenance therapy. An open oral food challenge to 8 g 
of cow’s milk protein followed. Fifteen of the 30 enrolled sub-
jects were able to pass the final 8 g oral challenge (1/10 in the 
SLIT group; 8/10 in the OIT A group and 6/10 in the OIT B 
group). Thus, this study showed that SLIT + OIT is more effec-
tive than SLIT alone in achieving desensitization most likely 
due to the much higher cumulative allergen dose achieved in 
the SLIT + OIT group.
At the end of the desensitization phase, the investigators in 
this study elegantly examined for the development of tolerance 
(see below). The 15 subjects who passed the DBPCFC after the 
desensitization period underwent a trial of 1 and 6 weeks off 
oral maintenance therapy. One week off of therapy, 2 subjects 
lost tolerance. Six weeks off of therapy 3/8 in OIT A group and 
3/6 in OIT B group lost tolerance. The loss of desensitization in 
these patients suggests that a longer maintenance treatment 
protocol (>48 weeks) may be required to ensure the develop-
ment of tolerance. However, the lowest reaction threshold in 
the six subjects who lost tolerance occurred at about 75 mL of 
milk, which is much higher than that of the 1st food challenge 
at the start of therapy (median <5 mL) and well above most ac-
cidental exposures. This finding indicates that although desen-
sitization can be lost after 6 weeks of milk avoidance, patients 
were still relatively protected against accidental exposures.
 
- Egg OIT
In a study of egg OIT, Buchanan et al.
37 enrolled 7 children with 
egg allergy, median age 48 months. The modified rush phase 
started with 0.1 mg of egg, followed by doubling doses every 30 
minutes. During the build up phase, the maximal tolerated dose 
at the end of the rush phase was given, followed by biweekly in-
creases of 25 mg until 150 mg was reached. At that point, in-
creases of 50 mg were administered at each visit until the final 
goal dose of 300 mg was reached. This maintenance dose was 
Study Averse events Nature Interventions Withdrawal rate
Jones
(Peanut)
- 36 (92%) had symptoms during 
initial escalation day
- 3.7% of total home doses 
Escalation phase:
- Upper respiratory
Symptoms (mild sneezing/itch-
ing and mild laryngeal Symp-
toms): 27 patients (69%) 
- Mild to moderate nausea or ab-
dominal pain: 17 patients (44%) 
- Mild diarrhea/emesis: 8 patients 
(21%)
- Mild or moderate skin symptoms 
24 subjects (62%) 
- Mild wheezing: 6 (18%)
Home dosing:
- Upper respiratory: (1.2%)
- Skin (1.1%) 
- Escalation phase:
Any treatment: 22 patients 
(56%)
Epinephrine: 4 (10%)
Diphenhydramine: 19 (49%)
- Home dosing:
Any treatment: 0.8% of total 
doses
Epinephrine: once for 2 patients
- 10 patients (25%) after dose es-
calation phase
Reasons:
- 6 for personal issues (transporta-
tion, parental anxiety, and fail-
ure to perform home dosing)
- 4 because of persistent allergic 
reactions to OIT
Blumchen
(Peanut)
Rush Phase: 7.9% of total doses
Long term with maintenance: 
2.6%
- Rush phase:
Gastrointestinal: 3.5% 
Skin Symptoms: 3.2%
Respiratory: 2.8%
- Build up/Maintenance:
Respiratory: 1.3%
Gastrointestinal: 0.9%
- Epinephrine: not used
- Salbutamol and cetirizine 
and/or prednisolone: 1.6% of 
total doses in rush phase versus 
0.3% of total doses in build up/
maintenance phase
- Cetirizine and/or predniso-
lone: 0.6% in rush phase versus 
0.08% in build up/maintenance
- Dropout rate: 35% (8/23) 
- Rush protocol: 1 dropout during 
because of anxiety
- Long term build up phase:
- 4 due to SEs
- 2 due to compliance
- 1 due to severe infection
Buchanan
(Egg)
- Only during rush phase
- Generally mild
- 1 did nt require any treatment
- 1 reaction only during the build 
up phase
- Skin erythema
- Skin pruritus
- Emesis
- Sneezing
- Rhinorrhea
- Abdominal pain
- Nasal congestion
- Urticaria
- Hypotension
- Oral pruritus
- Epinephrine: none
- Diphenhydramine: 6 patients 
in rush phase versus once in one 
patient in build up phase
- Intravenous fluids: 1 patient 
for mild transient hypotension 
(rush phase)
No withdrawal
Table. (Continued from the previous page) Safety of oral immunotherapyKhoriaty et al.
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then given daily at home, for a period of 24 months. A DBPCFC 
was done at the end of the OIT protocol and showed a signifi-
cant increase in the tolerated doses of egg protein compared to 
the rush phase and an increase in the mean cumulative dose of 
egg protein associated with adverse reactions from 0.05 g at the 
beginning of the study to 11.93 at the end (P=0.008). Limitations 
of this study were its small cohort size, the absence of a history 
of severe clinical reaction to egg ingestion at recruitment and 
the lack of a control group and therefore the possibility of oc-
currence of spontaneous natural tolerance. Although the 300 
mg maintenance dose was not enough to induce long-term tol-
erance in all patients, it was enough to protect against most ac-
cidental exposures to egg.
 
- Peanut OIT
Peanut OIT may be a greater challenge than milk or egg OIT, 
since peanut allergy usually does not resolve spontaneously, 
and more severe reactions may occur. In an open label study of 
peanut OIT by Jones et al.
38 39 subjects, aged 1 to 16 years, with 
baseline IgE levels >7 kU/L and a clinical reaction within the 
previous 6 months were enrolled. The study was divided into 3 
phases: 1) Initial escalation day with a starting dose of 0.1 mg of 
peanut protein followed by doubling doses every 30 minutes 
up to 50 mg; 2) build up phase: starting with the highest dose 
tolerated at the end of escalation phase and followed by gradu-
al spaced dose increases up to 300 mg (25 mg increase every 2 
weeks for subjects who have reached 50 mg at the end of esca-
lation; doubling doses every 2 weeks to reach 50 mg followed 
by 25 mg increases for those who could not reach the desired 
50 mg at the end of escalation phase); 3) maintenance phase of 
variable length with a median of 4.7 months (range, 4-22 months). 
10 patients (25%) withdrew from the study after the dose esca-
lation phase for either personal reasons or allergic reactions to 
OIT. In a post-maintenance OFC, 27 of the 29 remaining sub-
jects (93%) were able to ingest a total dose of 3.9 g of protein 
whereas the remaining 2 subjects stopped at doses lower or 
equal to 2.1 g of peanut protein.
Another trial of peanut OIT was recently described by Blum-
chen et al.
39 23 patients with a median age of 5.6 years and me-
dian baseline peanut-specific IgE levels of 95.6 kUA/L were en-
rolled. Peanut was administered at a starting dose equivalent to 
1/100 of the eliciting reaction dose during an initial DBPCFC 
and the dose was gradually increased over a period of 7 days, at 
a frequency of 2 to 4 times a day (Rush phase). Patients who 
failed to achieve the top 500 mg peanut dose in this period of 
time were given incremental doses every 2 to 4 weeks (build up 
phase) until the highest dose up to 500 mg was achieved. All 
patients continued on maintenance phase for 8 weeks, fol-
lowed by complete peanut avoidance for 2 weeks. Final DBP-
CFC showed a median 4 fold increase in the tolerated amount 
of peanut when compared to baseline OFC. Out of the 23 en-
rolled patients, 14 patients were fully desensitized tolerating a 
peanut dose of 0.5 to 2 g and 1 patient was partially desensitized 
(0.2 g). The remaining 8 patients dropped out of the study (1 dur-
ing rush phase for anxiety and 7 during long-term build-up 
protocol due to side effects and compliance issues).
SUMMARY OF OIT
The combined results of these studies indicate that OIT for 
food allergy is effective in increasing the amount of food toler-
ated in approximately 50% to 75% of the treated patients.
33-35,37-39 
A subset of patients however, appears to be resistant to oral de-
sensitization: 10%-20% of patients withdraw due to adverse re-
actions, and another 10%-20% achieves only partial desensiti-
zation. This suggests that patients are heterogeneous, and that 
some patients are easier to desensitize than others.
Identification of patients who may be resistant to desensitiza-
tion may be important since these protocols are being consid-
ered for use in community clinical practice. Therefore, these 
patients, who often develop significant allergic reactions, might 
be excluded from community-based protocols. High levels of 
food specific IgE may identify some of these patients, since in 
the peanut OIT study conducted by Blumchen et al.,
39 patients 
who failed to reach the goal of 500 mg had a median peanut 
specific IgE of 212 kUA/L (range: 14.3-2,071 kUA/L), whereas 
patients who tolerated 500 mg of peanut or more had a median 
baseline peanut-specific IgE of 9.1 kUA/L (range: 2.97-27 kUA/
L). Similarly, the 3 patients, in Meglio’s milk OIT study,
33 who 
failed desensitization and experienced severe adverse reactions 
with minimal amounts of milk, were found to have the highest 
baseline allergen-specific IgE (class 4 or 5 for casein and/or 
β-lactoalbumin). This correlation however, is not absolute, as 
one of the fully desensitized patients had a class of level 5 of 
milk-specific IgE. In addition, in the egg OIT study conducted 
by Buchanan et al.,
37 the study subject who had the highest IgE 
level was successfully desensitized and was able to pass the first 
food challenge without any adverse effects.
 
Safety
Most patients experienced at least one adverse event over the 
course of the study. Reactions varied in intensity from mild dis-
comfort to severe reactions that required treatment and occa-
sional subject withdrawal from the study. No life threatening 
event or death has been reported in any of the OIT protocols so 
far. Although reactions occurred at all times during the study 
period, the majority took place during the initial rush phase/
rapid escalation phase. Importantly, the frequency and severity 
of side effects may be lower when prophylactic antihistamines 
were administered,
33,35 by not having a rush phase, by having 
longer escalation or maintenance phases, or by omitting sub-
jective symptoms scoring (Table).Oral Immunotherapy for Food Allergy
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Long term efficacy and tolerance
Although previous studies have demonstrated short-term ef-
ficacy with induced desensitization, data on the long-term effi-
cacy of immunotherapy is limited. Moreover, whether desensi-
tization will lead to tolerance, as defined by the ability of the pa-
tient to stop oral intake of the food for a specified length of time 
and later pass an oral challenge to the food, is not yet clear. The 
development of tolerance, as defined in this way, may suggest 
“cure” , although the “specified length of time” currently is quite 
short, on the order of weeks to a few months. In the study by 
Staden et al.,
40 in which children with milk or hen’s egg allergy 
received either OIT or elimination diet, the persistence of oral 
tolerance in subjects who were successfully desensitized by OIT 
was evaluated by elimination diet for a period of 2 months. Only 
36% of the desensitized subjects developed tolerance, which 
was comparable to the rate in the elimination group (natural 
tolerance).
A shorter period of elimination diet of 2 weeks was used by 
Blumchen et al.
39 as part of their protocol on peanut oral immu-
notherapy. A DBPCFC done at the end of the elimination diet 
showed that 11 of the 14 desensitized patients tolerated the 
same or higher amounts of peanut compared to the maximal 
achieved maintenance dose, and the remaining 3 tolerated less. 
Similarly, Buchanan et al.
37 tested tolerance and long term effi-
cacy of their protocol on egg OIT by performing a DBPCFC fol-
lowing a 3 to 4 months period off egg. Two of the 4 patients who 
had passed the first challenge, passed the second with no reac-
tion.
One of the best studies of tolerance was that by Keet et al.
36 of 
milk desensitized patients. In this study, the patients received 
48 weeks of daily oral maintenance treatment before stopping 
oral maintenance for 6 weeks. Surprisingly, only 9 of 15 patients 
remained desensitized after the 6-week period off of mainte-
nance milk therapy.
These results together suggest that oral desensitization does 
not quickly lead to tolerance, even when the defining period off 
of the food is short (e.g., two weeks). Although some individu-
als may develop tolerance quickly, it is possible that a longer 
period of daily maintenance treatment will be required for most 
of the patients to develop tolerance, similar to the maintenance 
period for SCIT for inhaled allergens or for bee venom (>3-5 
years).
 
OIT USE IN ROUTINE CLINICAL PRACTICE
A goal of the experimental studies of OIT is to develop a safe 
protocol that can be performed in routine clinical practice with-
out too much concern for allergic reactions. While the current 
experimental results indicate that OIT is still associated with 
significant allergic reactions, which can often occur unexpect-
edly, some physicians have started OIT protocols in communi-
ty settings. This has generated some controversy for several rea-
sons, as discussed below.
Heterogeneity in protocols
The most important concern is that the best, safest and most 
efficacious clinical protocol has not been established. Compar-
ison of the safety and efficacy profile of the various trials is ex-
tremely difficult, because of the heterogeneity of the protocols 
utilized in different studies. Differences in protocol lengths and 
design, differences in measurement tools and proof of existence 
of true food allergy, heterogeneous and complex patient popu-
lation, degree of follow up, natural spontaneous tolerance espe-
cially in studies that lacked a placebo group as well as a possi-
bility of enrollment of food-tolerant patients because of a lack 
of baseline DBPCFC in some studies, can all together make 
comprehensive comparisons of the different protocols extreme-
ly difficult. Therefore, there is a need for more studies with larg-
er numbers of patients recruited in each study in order to in-
crease the evidence to support broadened use of OIT for food 
allergy.
Patient factors
Selecting patients for OIT based on the presence of allergy 
documented by history and laboratory parameters is not suffi-
cient to ensure the success and safety of OIT. Because of the 
safety issues and the length of the protocol, patients and their 
families must be extremely compliant, reliable and committed 
to the protocol. Moreover, because there may be a long mainte-
nance therapy period, the patient must be motivated and have 
a strong desire to eat the food as part of their normal diet. Dedi-
cating appropriate time for participation and follow up is very 
challenging due to scheduling and life styles constraints, but is 
required for successful completion of OIT.
Failure of desensitization
Despite the relatively good results of oral immunotherapy, a 
large fraction of the patients fail desensitization. Delineating 
predictive factors for a response to OIT early on is important for 
choosing and guiding therapy. Factors as age at entry, baseline 
levels of allergen specific IgE, presence of atopic disease and 
other food allergies may carry prognostic significance. In addi-
tion, OIT has been studied primarily in the context of IgE-me-
diated food allergy, and patients with complicated IgE-mediat-
ed and non-IgE-mediated disease may not respond well to OIT.
Costs
In addition, because OIT protocols are lengthy and require 
close medical monitoring for anaphylaxis, they are expensive, 
causing concern for health insurance coverage. To date, OIT 
protocols are considered by many to be experimental and risky, 
and are also not approved in the US by the FDA. Therefore, the 
procedure will be difficult to disseminate until it receives FDA 
approval and health insurance coverage.Khoriaty et al.
Allergy Asthma Immunol Res. 2013 January;5(1):3-15.  http://dx.doi.org/10.4168/aair.2013.5.1.3
Volume 5, Number 1, January 2013
10 http://e-aair.org
POSSIBLE IMPROVED APPROACHES WITH OIT
As discussed above, because current protocols for OIT are 
lengthy and associated with significant side effects, with some 
patients not responding, additional protocols are being exam-
ined to address the problems of safety and unresponsiveness to 
desensitization. A number of preclinical approaches are being 
considered, including use of adjuvants to more quickly induce 
“protective” immune responses and better antigens with re-
duced allergenicity. The use of mutated recombinant proteins 
instead of native food allergens can decrease the risk of adverse 
reactions during immunotherapy because of decreased IgE-
binding activity. A protective immune response may be further 
enhanced by coadministration of the mutated epitopes with 
bacterial adjuvants such as nonpathogenic strains of heat-killed 
Escherichia coli.
41,42 A mixture of different herbs used in Tradi-
tional Chinese Medicine has also been shown to have a protec-
tive effect in murine models of peanut-induced anaphylaxis
43-46 
and is currently being investigated in human clinical trials (us-
ing a simplified herbal formula FAHF-2, Food Allergy Herbal 
Formula 2).
47 In addition, a protocol combining OIT with treat-
ment with anti-IgE monoclonal antibody has been recently ex-
amined, as discussed below.
ANTI-IGE IN THE TREATMENT OF FOOD ALLERGIES
Anti-IgE monoclonal antibodies: Omalizumab is a recombi-
nant humanized monoclonal IgE-blocking antibody. Its de-
creases or prevents the allergic response triggered by IgE mole-
cules, by binding to the constant domains of free circulating IgE 
molecules, preventing by means of steric hindrance, binding to 
high affinity (FcεRI) and low affinity (FcεRII) receptors on ba-
sophils and mast cells reducing IgE-mediated mast cell and ba-
sophil degranulation on allergen exposure.
48-50 By greatly reduc-
ing the level of circulating free IgE (although levels of circulat-
ing bound IgE increases) omalizumab also decreases IgE from 
biding to FcεRI on dendritic cells. Moreover, omalizumab treat-
ment down regulates FcεRI expression on basophils, mast cells 
and dendritic cells.
51 The reduced expression of FcεRI on den-
dritic cells is thought to reduce allergen presentation to T cells, 
followed by a reduction in Th2 cell activation, and a consequent 
decreased production of Th2 cytokines during the effector 
phases of allergic diseases.
52
Because omalizumab does not bind to the variable allergen 
specific region of IgE molecules, it is an allergen non-specific 
modality of treatment. Subcutaneous injections of omalizumab 
have been shown to have relatively few and tolerable side effects 
mainly at the injection site. Less common observed reactions 
included bronchospasm, hypotension, syncope, urticaria, an-
gioedema and rarely anaphylaxis.
53-55
Omalizumab in refractory asthma and allergic rhinitis
Omalizumab has been shown to be effective in reducing symp-
toms and the steroid requirements of allergic asthma, particu-
larly in patients with moderate to severe asthma, and was ap-
proved by the FDA in 2003 for the treatment of moderate to se-
vere asthma not responsive to other conventional treatments.
48 
In addition, although not approved by the FDA for this indica-
tion, omalizumab is also effective in reducing symptoms in pa-
tients with seasonal allergic rhinitis.
56
Omalizumab has also been studied in combination with rush 
SCIT for allergic rhinitis. Such a combination was shown to in-
crease the safety and efficacy of ragweed rush immunotherapy 
when compared to immunotherapy alone.
57 Patients, aged 18 
to 50 years were randomized in a 1:1:1:1 ratio to 4 groups: 1) 
omalizumab and immunotherapy; 2) omalizumab only; 3) im-
munotherapy only; 4) placebo. Omalizumab was administered 
subcutaneously at a minimum dose of 0.016 mg/kg/IgE (IU/
mL)/mo every 2 or 4 weeks, depending on weight and baseline 
IgE levels. Patients who received omalizumab were found to 
have less adverse events and a 5-fold decrease in the risk of 
anaphylaxis, as well as a significant improvement in severity 
scores during ragweed season when compared to those receiv-
ing immunotherapy alone. The addition of omalizumab was 
therefore thought to significantly improve the safety profile of 
rush immunotherapy, and to permit more rapid and higher 
doses of allergen immunotherapy.
54 However, because rush im-
munotherapy has not been traditionally used in clinical prac-
tice for allergic rhinitis, and because omalizumab is not FDA 
approved in the US for this indication, omalizumab enabled 
rush immunotherapy for hay fever has not been utilized in clin-
ically practice.
Anti-IgE monoclonal antibodies in peanut allergy
Another humanized anti-IgE mAb, TNX-901 is similar to 
omalizumab in binding free IgE. TNX-901 was shown to im-
prove the dose of peanut tolerated during an oral peanut chal-
lenge, suggesting that it might be effective in preventing allergic 
symptoms on accidental ingestion of peanuts. In this study, 84 
patients with peanut allergy were randomly assigned, in a 3:1 
ratio, to receive 150 mg, 300 mg, or 450 mg of TNX-901 or place-
bo subcutaneously every 4 weeks for 4 doses. DBPCFC were 
performed at the start and at the end of the study and results 
were compared. Prior to peanut challenge, patients tolerated 
an average up to 436 mg of peanut flour, whereas after treat-
ment with the highest dose of TNX-901, patients tolerated six 
times more peanuts. This study suggested that treatment with 
anti-IgE mAb could reduce the likelihood of anaphylaxis on ac-
cidental peanut ingestion, but it did not assess the role of anti-
IgE therapy on enhancing desensitization to peanuts.
58
Omalizumab in peanut allergy
A similar phase II, multicenter, randomized, double-blind, Oral Immunotherapy for Food Allergy
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placebo-controlled, parallel-group trial using omalizumab was 
initiated to replicate the findings with TNX-901 in peanut aller-
gy. Patients with a history of immediate reaction to peanut, pos-
itive SPT to peanut and/or detectable peanut specific (IgE >0.35 
kUA/L) were randomly assigned, in a 2:1 ratio, to receive either 
omalizumab or placebo every 2 to 4 weeks for 20 to 22 weeks 
with the minimum dose of omalizumab/study drug being 0.016 
mg/kg/IgE (IU/mL) every 4 weeks. DBPCFC were conducted at 
the beginning and at the end of the study. However, the study 
was halted because of two severe anaphylactic reactions that 
occurred during the first DBPCFC, before omalizumab admin-
istration. Therefore, only 14 subjects were able to reach the 
study’s primary endpoint. Six (44%) of omalizumab treated pa-
tients and three (20%) of placebo treated patients could tolerate 
>1,000 mg of peanut flour during the post therapy food chal-
lenge at 24 weeks. Although data was limited, there appeared to 
be statistical significance in the increase in maximum tolerable 
peanut dose from baseline pre therapy values in omalizumab 
treated group when compared to placebo treated group.
59
Omalizumab oral desensitization combination therapy in 
significant IgE-mediated cow milk allergy
Since omalizumab can reduce allergic symptoms that occur 
with peanut administration, a phase I pilot study was recently 
performed assessing the safety and efficacy of combining 
omalizumab treatment with OIT in young children with signifi-
cant cow milk allergy. The long term goal of the study was to 
improve the safety of and reduce the length of time required for 
effective cow’s milk OIT. Eleven patients, aged 7 to 17 years, with 
a significant history of IgE-mediated cow milk allergy including 
anaphylaxis were enrolled at two centers with US Food and Drug 
Administration approval. Milk allergy was documented by his-
tory of acute clinical reaction upon exposure to milk, positive 
skin test to milk (median wheal/flare 20/50 mm; wheal/erythe-
ma diameter, range 11-45/20-52 mm), high milk-specific IgE 
levels (median 50 kUA/L; range, 41.6-342 kUA/L) and elevated 
total serum IgE (median 349 kU/L; range, 148-2,593 kU/L).
The study was divided into three phases: 9 weeks of omali-
zumab pretreatment; 7 to 11 weeks of oral desensitization with 
omalizumab treatment; 9 weeks of maintenance OIT off of 
omalizumab before a DBPCFC at week 24 (Figure). All patients 
received open-label omalizumab (anti-IgE mAb; Xolair; Genen-
tech, San Francisco, CA, USA) with a dosing schedule based on 
the package insert for children with IgE levels below 700 kU/L. 
For children with total serum IgE levels >700 kU/L, the dose 
was approximately 0.016 mg/kg/IgE U/mL (225 to 300 mg) ev-
ery 2 weeks.
The desensitization phase was further subdivided into two 
phases: a rush phase occurring over 6 hours and a slower esca-
lation phase (weeks 9 to 16). The rush phase began with the ad-
ministration of 0.1 mg of cow’s milk protein followed by 11 in-
cremental doses every 30 minutes and reaching a maximum 
Figure. Study protocol: Rapid oral desensitization in combination with Omalizumab (xolair) therapy in patients with cow’s milk allergy. DBPCFC, double blind placebo 
controlled food challenge.Khoriaty et al.
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dose of 1,000 mg (cumulative dose 1,992 mg). The subsequent 
dose escalation phase consisted of the highest dose of milk 
achieved during the rush desensitization given daily for one 
week, followed by weekly increase of 12.5%, with doses given 
daily over the course of each week. During the initial one-day 
rush phase, 9 of the11 subjects reached the maximal dose of 
1,000 mg (cumulative dose 1,992 mg). One subject voluntarily 
withdrew from the study due to abdominal migraines. Two 
subjects experienced adverse reactions during the process: 1 
subject developed, after the 1,000 mg dose (cumulative dose 
1,990 mg), nasal obstruction and generalized urticaria refracto-
ry to diphenhydramine and cetirizine and was treated with epi-
nephrine; another had symptoms at the 7 mg dose. During the 
slower escalation phase, 9 out of 10 remaining subjects reached 
the maximal daily dose of 2,000 mg and the subject who previ-
ously received epinephrine, reached a dose of 1,200 mg. After 
the desensitization, all subjects were instructed to continue dai-
ly milk intake (maintenance phase), and the omalizumab was 
discontinued.
On week 24, a DBPCFC with a top dose of 3,000 mg (cumula-
tive dose 7,250 mg) was performed. Allergic reactions occurring 
during the protocol were graded based on the scoring system 
developed by Bock et al.
60 All 9 patients who reached the dose 
of 2,000 mg during desensitization phase, passed the challenge 
and were instructed to continue with daily milk ingestion 
>8,000 mg/day.
61 The one patient who was only able to reach a 
dose of 1,200 mg by the 7th week in dose escalation phase de-
veloped generalized urticaria and rhinitis at the 2,000 mg dose 
during the DBPCFC, and was treated with antihistamines. He 
was continued on a dose of 1,000 mg/day, and was later able to 
increase his daily dose to 4,000 mg (120 mL/day).
This study, the first to use omalizumab in combination with 
milk OIT, demonstrated that such a combination approach is 
safe and feasible, and might allow for faster desensitization of 
patients with food allergy, without an increase in allergic reac-
tions. In this study, allergic reactions associated with the desen-
sitization were primarily mild and no serious life-threatening 
events were observed. Importantly, the 9 of 9 patients who com-
pleted the desensitization were able to include large amounts of 
milk in their diets. By week 24 in the study, the 10th patient 
could take >1,000 mL of milk, and this dose has increased 
gradually over time.
Despite showing that this procedure is relative safe and effica-
cious, this study does have limitations: small sample size, ab-
sence of a DBPCFC at study initiation and absence of a placebo 
group. However, based on the results of this pilot study, this ap-
proach with omalilzumab has been extended, and is now being 
studied in three different studies at three institutions in patients 
with milk allergy (Mt. Sinai), with peanut allergy (at Duke Uni-
versity and at Children’s Hospital Boston, Harvard Medical 
School). In the peanut study at Children’s Hospital Boston, sub-
jects aged 7 to 25 years, with severe IgE-mediated peanut aller-
gy are being enrolled, with patients having peanut specific IgE 
>20 kUA/L, total IgE values between 50 and 2,000 kU/L and a 
reaction to a DBPCFC at a peanut dose of 100 mg or less. Omal-
izumab is being administered subcutaneously once every 2 or 4 
weeks for a period of 19 weeks, with oral desensensitization oc-
curring in the last 7 weeks of the omalizumab treatment. The 
primary outcome is the ability to tolerate a dose of 500 mg (cu-
mulative 1,000 mg) following the first day of desensitization and 
a dose of 4,000 mg following 7 weeks (build up phase) of OIT.
In the peanut study at Duke University, the primary objective 
is to test whether the addition of omalizumab to peanut OIT 
can lead to subject desensitization in a safer, faster and more ef-
fective manner, and whether it can achieve long term tolerance. 
Subjects aged 12 years and above with a history of significant 
reaction to peanut, SPT to peanut with a wheal diameter of >3 
mm and peanut-specific IgE >5 kUA/L are eligible. Omalizum-
ab will be administered as pretreatment drug before OIT and 
will be kept until one month after maintenance phase. OIT will 
consist of 2 days of initial desensitization followed by a 4 month 
build up phase. Subjects will then be randomly assigned to ei-
ther 12 or 24 months of maintenance with a goal of tolerating 
8,000 mg of peanut powder. Desensitization will be tested by a 
post maintenance OFC and tolerance will be tested by a post 4 
weeks elimination diet OFC.
In the study at Mt. Sinai, the aim is to compare the efficacy 
and safety of a combination of omalizumab and OIT with OIT 
alone. Subjects will be randomized to receive either omalizum-
ab or placebo. DBPCFC will be performed at several times dur-
ing the study. At the end of the study, the percentage of desen-
sitized individuals in each arm of the study will be calculated 
and results will be compared. Furthermore, tolerance will be 
evaluated in those who have achieved desensitization after 
complete milk discontinuation for a certain period of time.
CONCLUSION
The studies summarized above have shown that OIT can suc-
cessfully desensitize a large number of patients without major 
morbidity or mortality. Data on the risk of life threatening events 
though, is limited and longer follow up of a bigger sample size 
is needed before ascertaining overall long term safety of immu-
notherapy. At the end of all of the studies, patients can tolerate 
more of the food than at the start. Successful completion of OIT 
reduces the risk of serious reaction on accidental ingestion, and 
in some studies, particularly the one with omalizuamb, many 
patients can tolerate normal amounts of the food in their diet 
without symptoms. It should be emphasized however, that in 
all of the published studies, the enrolled study patient popula-
tions have been highly motivated, and willing to accept the risks 
of reactions in these experimental protocols. While the ultimate 
goal is to extend OIT protocols to the general public as a stan-
dard medical therapy, it is clear that OIT protocols require ab-Oral Immunotherapy for Food Allergy
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solute and full patient cooperation. Although in some protocols, 
prevention of serious allergic reactions on accidental ingestion 
is the goal, in studies with omalizumab, in which the goal is to 
extend the diet to include a food that was previously proscribed 
and possibly never tasted, patient motivation is an extremely 
important consideration.
While achieving desensitization to a food to which the patient 
was previously allergic can dramatically improve the quality of 
life of patients, it is not yet clear if a full “cure” of food allergy can 
be achieved with OIT. The few studies that have examined “tol-
erance” have shown that only a fraction of patients develop tol-
erance and only when the food avoidance period after success-
ful desensitization is short (generally <2 months). Whether tol-
erance can be observed after much longer periods of food avoid-
ance after successful desensitization is yet to be determined. 
Practically speaking however, it may not be necessary to have 
very long periods of food avoidance, if the goal of OIT is to add 
the food to the diet, even in small quantities.
Nevertheless, even without tolerance, OIT could offer a rea-
sonable new therapy for patients with food allergy. Future stud-
ies however, must focus on developing a standardized and safe 
protocol that is safe and reasonably easy to perform in the com-
munity. The final protocol will need to formalize specific entry 
criteria, treatment dosages, maintenance dosages and optimal 
followup. For patients with severe disease and high allergen-
specific IgE, inclusion of anti-IgE monoclonal antibodies may 
be useful. Investigators and clinicians need to weigh risks and 
benefits of specific interventional approaches, reach at a com-
bined decision with patients and families and be committed to 
ensuring the success and safety of the suggested protocol. It is 
important to carefully assess all parameters and individualize 
each patient’s treatment accordingly and guided by scientific 
evidence.
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